Scarica l'app Stockscreener
1.395
5.74%
-0.085
Dopo l'orario di chiusura:
1.38
-0.015
-1.08%
Precedente Chiudi:
$1.48
Aprire:
$1.43
Volume 24 ore:
607.25K
Relative Volume:
5.76
Capitalizzazione di mercato:
$6.00M
Reddito:
-
Utile/perdita netta:
$-7.50M
Rapporto P/E:
-0.3168
EPS:
-4.4035
Flusso di cassa netto:
$-6.14M
1 W Prestazione:
-9.42%
1M Prestazione:
-15.45%
6M Prestazione:
-29.19%
1 anno Prestazione:
-71.30%
Intervallo 1D:
$1.31
$1.44
Intervallo di 1 settimana:
$1.31
$1.6299
Portata 52W:
$1.31
$8.34
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Nome
Acurx Pharmaceuticals Inc
Settore
Industria
Telefono
917-533-1469
Indirizzo
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
1.395 | 6.62M | 0 | -7.50M | -6.14M | -4.4035 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ACXP: Advanced ibezapolstat program, secured funding, and expanded patent estate for CDI treatment - TradingView
Earnings call transcript: Acurx beats Q2 2026 EPS forecast but shares slip premarket - Investing.com
Acurx Pharmaceuticals Q2 Results: EPS misses estimate, losses widen - scanx.trade
Acurx Pharmaceuticals reports Q2 2026 results, advances antibiotic trials, and strengthens patent portfolio. - Pluang
Acurx Q2 2026 earnings: per-share loss narrows as share count rises - TradingKey
Acurx Receives Conditional FDA Acceptance for C. difficile Drug Name - Stock Titan
ACXP: Net loss narrowed, but cash runway is short; new funding is needed to sustain clinical progress - TradingView
Acurx Pharmaceuticals (ACXP) trims losses and raises $6.2M to fund antibiotic pipeline - Stock Titan
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
New patents cover Acurx antibiotics targeting DNA Polymerase IIIC - Stock Titan
Acurx and Leiden Researchers Seek 3D Structure to Guide MRSA Antibiotics - Stock Titan
ACXP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program - TradingView
FDA Provides Further Regulatory Guidance to A - Moomoo
Acurx's ~550-Patient Trial Could Support C. diff Treatment, Recurrence Reduction - Stock Titan
Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.440|Chg%:+0.020 - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.395|Chg%:-0.085 - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Institutional Confidence - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
TradingKey - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Cash Flow - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.435|Chg%:+0.015 - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.400|Chg%:-0.030 - TradingKey
Acurx Pharmaceuticals (ACXP) Income Statement & Earnings - Moomoo
Acurx Pharmaceuticals (ACXP) Registration filing Summary - Quartr
Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection - Yahoo Finance Singapore
Acurx data: beneficial gut bacteria remain after repeated C. diff. courses - Stock Titan
Price to earnings forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals Inc. (ACXP) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update - Yahoo Finance
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - AOL.com
Acurx Pharmaceuticals (ACXP) Slides 8.23% as Stock Tests Key Support at $1.38MA Crossover - dars.gov.et
Acurx Pharmaceuticals outlines its antibiotic pipeline as investors weigh long-term prospects - Ad-hoc-news.de
Acurx Pharmaceuticals (ACXP) Stock Analysis Report | Financials & Insights - Benzinga España
What date does Acurx Pharmaceuticals's (ACXP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Clostridium Difficile Infections Market Forecast Signals - openPR.com
ACXP Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Gains on Operational Updates - dars.gov.et
Price to book forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Price to book forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView
Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Acurx Pharmaceuticals Inc Azioni (ACXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):